Vanguard Group’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $31.5M | Buy |
2,326,449
+290,943
| +14% | +$3.94M | ﹤0.01% | 2335 |
|
|
2025
Q1 | $32.3M | Buy |
2,035,506
+603,464
| +42% | +$9.58M | ﹤0.01% | 2282 |
|
|
2024
Q4 | $17.6M | Buy |
1,432,042
+68,811
| +5% | +$847K | ﹤0.01% | 2643 |
|
|
2024
Q3 | $16.5M | Buy |
1,363,231
+144,169
| +12% | +$1.75M | ﹤0.01% | 2689 |
|
|
2024
Q2 | $14.3M | Buy |
1,219,062
+236,130
| +24% | +$2.76M | ﹤0.01% | 2726 |
|
|
2024
Q1 | $12.7M | Buy |
982,932
+4,952
| +0.5% | +$63.9K | ﹤0.01% | 2832 |
|
|
2023
Q4 | $8.41M | Buy |
977,980
+40,342
| +4% | +$347K | ﹤0.01% | 3049 |
|
|
2023
Q3 | $8.92M | Buy |
937,638
+11,629
| +1% | +$111K | ﹤0.01% | 2943 |
|
|
2023
Q2 | $15.8M | Buy |
926,009
+634,281
| +217% | +$10.8M | ﹤0.01% | 2694 |
|
|
2023
Q1 | $4.57M | Buy |
+291,728
| New | +$4.57M | ﹤0.01% | 3354 |
|